The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Open accessAbstract
Background & Aims: Although hepatitis B and C have been the main drivers of hepatocellular carcinoma (HCC), nonalcoholic steatohepatitis (NASH) has recently become an important cause of HCC. The aim of this study was to assess the causes of HCC among liver transplant (LT) candidates in the United States. Methods: The Scientific Registry of Transplant Recipients (2002–2016) was used to estimate the trends in prevalence of HCC in LT candidates with the most common types of chronic liver disease: alcoholic liver disease (ALD), chronic hepatitis B (CHB), chronic hepatitis C, and NASH. Results: 158,347 adult LT candidates were included. Of these, 26,121 (16.5%) had HCC; this proportion increased from 6.4% (2002) to 23.0% (2016) (trend P < .0001). Over the study period, CHC remained the most common etiology for HCC (65%). The proportions of HCC accounted for by CHC and ALD remained stable (both trend P > .10), the proportion of CHB decreased 3.1‐fold (P < .0001), while the proportion of NASH in HCC increased 7.7‐fold (from 2.1% to 16.2%; P < .0001). Furthermore, since 2002, the prevalence of HCC in LT candidates with NASH increased 11.8‐fold, while this rate increased 6.0‐fold in CHB, 3.4‐fold in ALD, and 2.3‐fold in CHC (all P < .0001); the increasing trend in NASH was steeper than that for any other etiology (P < .0001 in a trend regression model). The proportion of LT candidates with HCC who ultimately received a transplant or died while waiting did not differ between etiologies (P > .05). Conclusions: Nonalcoholic steatohepatitis is the most rapidly growing cause of HCC among US patients listed for liver transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationWong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Self-citationYounossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Self-citationWong, R. J., Cheung, R., & Ahmed, A. (2014) · Hepatology · doi:10.1002/hep.26986 · Cited by 723
Self-citationDavila, J. A., Morgan, R. O., Shaib, Y., McGlynn, K. A., & El-Serag, H. B. (2005) · Gut · doi:10.1136/gut.2004.052167 · Cited by 704
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
El-Serag, H. B., & Kanwal, F. (2014) · Hepatology · doi:10.1002/hep.27222 · Cited by 646
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
Ong, J. P., Pitts, A., & Younossi, Z. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.018 · Cited by 638
Self-citationYounossi, Z. M., Stepanova, M., Rafiq, N., Makhlouf, H., Younoszai, Z., Agrawal, R., & Goodman, Z. (2011) · Hepatology · doi:10.1002/hep.24268 · Cited by 638
Self-citation
Cited by
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Self-citationNon-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Self-citationGlobal epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Epidemiology and Management of Hepatocellular Carcinoma
Kulik, L., & El-Serag, H. B. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.065 · Cited by 1,735
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., Abdelmalek, M. F., & Suzuki, A. (2019) · Hepatology · doi:10.1002/hep.30626 · Cited by 1,050
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationPaik, J. M., Golabi, P., Younossi, Y., Mishra, A., & Younossi, Z. M. (2020) · Hepatology · doi:10.1002/hep.31173 · Cited by 788
Self-citationEpidemiological Features of NAFLD From 1999 to 2018 in China
Zhou, J., Zhou, F., Wang, W., Zhang, X., Ji, Y., Zhang, P., She, Z., Zhu, L., Cai, J., & Li, H. (2020) · Hepatology · doi:10.1002/hep.31150 · Cited by 678
Younossi, Z. M., Stepanova, M., Ong, J., Trimble, G., AlQahtani, S., Younossi, I., Ahmed, A., Racila, A., & Henry, L. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.064 · Cited by 576
Self-citationGlobal epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 553
Epidemiology of chronic liver diseases in the USA in the past three decades
Younossi, Z. M., Stepanova, M., Younossi, Y., Golabi, P., Mishra, A., Rafiq, N., & Henry, L. (2020) · Gut · doi:10.1136/gutjnl-2019-318813 · Cited by 549
Self-citationHuang, D. Q., Singal, A. G., Kono, Y., Tan, D. J. H., El-Serag, H. B., & Loomba, R. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.003 · Cited by 534
Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Kanwal, F., & Singal, A. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.049 · Cited by 471
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Davison, B. A., Harrison, S. A., Cotter, G., Alkhouri, N., Sanyal, A., Edwards, C., Colca, J. R., Iwashita, J., Koch, G. G., & Dittrich, H. C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.025 · Cited by 448
Hepatocellular carcinoma in the setting of alcohol-related liver disease
Ganne-Carrié, N., & Nahon, P. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.008 · Cited by 360
Epidemiology and risk-stratification of NAFLD-associated HCC
Ioannou, G. N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.012 · Cited by 361
Loomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 357
Le, M. H., Yeo, Y. H., Zou, B., Barnet, S., Henry, L., Cheung, R., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0239 · Cited by 357
Disease Burden of Hepatocellular Carcinoma: A Global Perspective
Sayiner, M., Golabi, P., & Younossi, Z. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05537-2 · Cited by 339
Self-citationHaldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., Teng, M., Syn, N., Lim, G., Yong, J. N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00078-x · Cited by 307
Long, M. T., Noureddin, M., & Lim, J. K. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.023 · Cited by 299
Best, J., Bechmann, L. P., Sowa, J.-P., Sydor, S., Dechêne, A., Pflanz, K., Bedreli, S., Schotten, C., Geier, A., Berg, T., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.11.012 · Cited by 288
Therapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
Wong, R. J., & Singal, A. K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20294 · Cited by 253
Self-citationOrci, L. A., Sanduzzi-Zamparelli, M., Caballol, B., Sapena, V., Colucci, N., Torres, F., Bruix, J., Reig, M., & Toso, C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.002 · Cited by 218
Choi, H. S. J., Brouwer, W. P., Zanjir, W. M. R., de Man, R. A., Feld, J. J., Hansen, B. E., Janssen, H. L. A., & Patel, K. (2020) · Hepatology · doi:10.1002/hep.30857 · Cited by 211
Luci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186
Younossi, Z. M., Stepanova, M., Ong, J., Yilmaz, Y., Duseja, A., Eguchi, Y., El Kassas, M., Castellanos-Fernandez, M., George, J., Jacobson, I. M., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.033 · Cited by 172
Gut–Liver Axis: How Do Gut Bacteria Influence the Liver?
Konturek, P. C., Harsch, I. A., Konturek, K., Schink, M., Konturek, T., Neurath, M. F., & Zopf, Y. (2018) · Medical Sciences · doi:10.3390/medsci6030079 · Cited by 168
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis
Zhu, C., Tabas, I., Schwabe, R. F., & Pajvani, U. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00365-6 · Cited by 112
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery
Pais, R., Aron‐Wisnewsky, J., Bedossa, P., Ponnaiah, M., Oppert, J., Siksik, J., Genser, L., Charlotte, F., Thabut, D., Clement, K., et al. (2022) · Hepatology · doi:10.1002/hep.32358 · Cited by 95
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
Luo, Y., Wadhawan, S., Greenfield, A., Decato, B. E., Oseini, A. M., Collen, R., Shevell, D. E., Thompson, J., Jarai, G., Charles, E. D., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1670 · Cited by 87
“(1) NASH has emerged as a major cause of liver-related morbidity and mortality worldwide.(2,3) The greater rate of mortality in affected individuals is related to cardiovascular events, liver-related outcomes, and cancers.”
BackgroundImprovement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention
O’Gorman, P., Naimimohasses, S., Monaghan, A., Kennedy, M., Melo, A. M., Ní Fhloinn, D., Doherty, D. G., Beddy, P., Finn, S. P., Moore, J. B., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15989 · Cited by 94
Wei, G., An, P., Vaid, K. A., Nasser, I., Huang, P., Tan, L., Zhao, S., Schuppan, D., & Popov, Y. V. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00041.2019 · Cited by 84
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression
Xue, J., Cao, Z., Cheng, Y., Wang, J., Liu, Y., Yang, R., Li, H., Jiang, W., Li, G., Zhao, W., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.043 · Cited by 72
Panunzi, S., Maltese, S., Verrastro, O., Labbate, L., De Gaetano, A., Pompili, M., Capristo, E., Bornstein, S. R., & Mingrone, G. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14304 · Cited by 61
Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver
Xia, M., Chandrasekaran, P., Rong, S., Fu, X., & Mitsche, M. A. (2021) · Journal of Lipid Research · doi:10.1194/jlr.ra120000856 · Cited by 60
Wang, X., Sommerfeld, M. R., Jahn‐Hofmann, K., Cai, B., Filliol, A., Remotti, H. E., Schwabe, R. F., Kannt, A., & Tabas, I. (2019) · Hepatology Communications · doi:10.1002/hep4.1405 · Cited by 56
Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease
Hagström, H., Kechagias, S., & Ekstedt, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13343 · Cited by 52
Obeticholic acid: towards first approval for NASH
Eslam, M., Alvani, R., & Shiha, G. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32963-0 · Cited by 43
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
Wang, Y., Wong, G. L.-H., He, F.-P., Sun, J., Chan, A. W.-H., Yang, J., Shu, S. S.-T., Liang, X., Tse, Y. K., Fan, X.-T., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318841 · Cited by 42
Self-citationTreatment Candidacy for Pharmacologic Therapies for NASH
Rowe, I. A., Wong, V. W.-S., & Loomba, R. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.005 · Cited by 41
Self-citationNon-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
Goldberg, D., Mantero, A., Newcomb, C., Delgado, C., Forde, K. A., Kaplan, D. E., John, B., Nuchovich, N., Dominguez, B., Emanuel, E., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.021 · Cited by 38
Mahapatro, A., Bawna, F., Kumar, V., Daryagasht, A. A., Gupta, S., Raghuma, N., Moghdam, S. S., Kolla, A., Mahapatra, S. S., Sattari, N., et al. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.07.087 · Cited by 37
MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
Loomba, R. (2021) · Hepatology · doi:10.1002/hep.31624 · Cited by 36
“(1) NASH can lead to cirrhosis, end-stage liver disease, and hepatocellular carcinoma and has become one of the leading indications for liver transplant in the United States.”
BackgroundBehari, J., Gougol, A., Wang, R., Luu, H. N., Paragomi, P., Yu, Y.-C., Molinari, M., Chopra, K., Malik, S. M., Geller, D., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000183 · Cited by 35
Shrestha, S., Jeon, J.-H., & Hong, C.-W. (2025) · BMB Reports · doi:10.5483/bmbrep.2024-0058 · Cited by 30
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Wallace, C., Gamkrelidze, I., Estes, C., Razavi, H., & Sanyal, A. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.009 · Cited by 27
Fujita, M., Chen, M.-J. M., Siwak, D. R., Sasagawa, S., Oosawa-Tatsuguchi, A., Arihiro, K., Ono, A., Miura, R., Maejima, K., Aikata, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34249-x · Cited by 24
Targeting MASLD and MASH in the US Hispanic/Latino Population: A Review
Cumpian, N. A., Gutierrez, J. A., Wu, W., & Saab, S. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.4769 · Cited by 22
miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression
Fernández-Tussy, P., Cardelo, M. P., Zhang, H., Sun, J., Price, N. L., Boutagy, N. E., Goedeke, L., Cadena-Sandoval, M., Xirouchaki, C. E., Brown, W., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.168476 · Cited by 21
“Ranging from metabolic dysfunction–associated steatotic liver (MASL) to metabolic dysfunction–associated steatotic hepatitis (MASH), MASLD can progress to severe fibrosis or cirrhosis, ultimately leading to end-stage liver disease or hepatocellular carcinoma (HCC) (9, 10).”
BackgroundGurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Verna, E. C., Phipps, M. M., Halazun, K. J., Markovic, D., Florman, S. S., Haydel, B. M., Ruiz, R., Klintmalm, G., Lee, D. D., Taner, B., et al. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000007 · Cited by 16
Metadata
- Authors
- Younossi, Z., Stepanova, M., Ong, J. P., Jacobson, I. M., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V. W., Negro, F., Yilmaz, Y., Romero-Gomez, M., George, J., Ahmed, A., Wong, R., Younossi, I., Ziayee, M., & Afendy, A.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 17
- Issue
- 4
- Pages
- 748-755.e3
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2808368206
- Cited by
- 806
- References
- 31
- FWCI
- 43.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.